Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KYNB with free AI briefings, catalyst countdowns, and dilution alerts.

KYNB · KYNTRA BIO, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$53.1M Cash, Pro Forma
17.8mo Cash Runway
Follow KYNB by email Get an email when KYNB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KYNB, unsubscribe in one click. Privacy

📣 What KYNB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Roxadustat (FG-4592) CKD Anemia in Dialysis Participants Phase 4 · NCT04059913 Completed
Therapeutic Corticosteroid Duchenne Muscular Dystrophy Phase 3 · NCT04632940 Terminated
SEPO® Chemotherapy Induced Anemia Phase 3 · NCT05301517 Completed
Pamrevlumab (FG-3019) Pancreatic Cancer Non-resectable Phase 3 · NCT03941093 Completed
Iron Anemia Phase 3 · NCT02278341 Completed
Sub-Study: Pirfenidone Idiopathic Pulmonary Fibrosis Phase 2 · NCT01890265 Completed
Nab-paclitaxel Pancreatic Cancer (Unresectable) Phase 1/2 · NCT02210559 Completed
IV Iron Dialysis Phase 2 · NCT01414075 Completed
Anti-CD46 Antibody-drug Conjugate FOR46 Metastatic Castration-resistant Prostate Cancer Phase 1/2 · NCT05011188 Active not recruiting
ASP1517 Healthy Subjects Phase 1 · NCT02952040 Completed
Zirconium Zr 89-DFO-YS5 Bladder Cancer Phase 1 · NCT07664397 Recruiting

Also used in these trials (approved or third-party drugs, not KYNB's own candidates): Darbepoetin Alfa, Epoetin Alfa, Nintedanib, Pegfilgrastim, Gemcitabine Hydrochloride, Enzalutamide, Lanthanum Carbonate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KYNB had $95.3M in cash and short-term investments on its Jun 30, 2026 balance sheet. Including the cash events since then, it holds about $53.1M pro forma, before operating spending after that date:

It burns about $8.9M/quarter from operations, an estimated runway of 17.8 months from Jun 30, 2026 at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 50 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KYNB files for a raise →

👥 Who Owns KYNB

Insiders 13.1% Institutions (41 holders) 24.6% Public and other holders 62.3%
HolderTypeShares% of sharesAs of
Armistice Capital, LLC Institution (13G, 5%+) 400,000 9.88% 2026-09-30
Christine Chung
SVP, CHINA OPERATIONS
Insider 294,903 7.28% 2025-03-06
Juan Graham
CHIEF FINANCIAL OFFICER
Insider 164,863 4.07% 2024-12-06
James A Schoeneck
Director · +127,000 options
Insider 39,666 0.98% 2025-06-30
Thane Wettig
CEO, Director · +1.36M options
Insider 26,836 0.66% 2026-09-06
David DeLucia
Chief Financial Officer · +551,000 options
Insider 4,355 0.11% 2026-09-06

Share count 4,049,985 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KYNB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KYNB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.